Skip to main content

Table 4 Comparative analysis of the clinical characteristics of hepatocellular carcinoma patients with different miR-196a2 genotypes

From: High-resolution melting analysis reveals genetic polymorphisms in MicroRNAs confer hepatocellular carcinoma risk in Chinese patients

Characteristic

Reference intervals

TT (n = 60)

CT (n = 209)

CC (n = 45)

P

Alanine amiotransferase (U/L)a

0-46

36.0 (22.8, 60.8)

39.0 (28.0, 78.3)

39.0 (31.0, 78.5)

0.364

Aspartate aminotransferase, (U/L)a

0-46

43.0 (30.0, 62.8)

46.0 (30.3, 85.5)

46.0 (35.0, 72.0)

0.468

Total bilirubin (μmol/L)a

0-25

20.7 (16.0, 29.6)

18.2 (13.0, 24.9)

18.3 (14.9, 24.7)

0.186

Direct bilirubin (μmol/L)a

0-7

5.9 (4.0, 8.5)

4.8 (3.5, 6.8)

5.3 (3.7, 7.1)

0.134

Indirect bilirubin (μmol/L)a

1.5-18

15.2 (11.7, 20.0)

13.7(9.6,18.9)

12.7 (9.5, 17.1)

0.227

Total protein (g/L)a

60-80

69.5 (64.4, 73.8)

68.1 (62.2, 74.0)

67.1 (61.7, 71.3)

0.215

Albumin (g/L)b

35-55

40.3 ± 5.0

40.4 ± 6.0

38.8 ± 6.8

0.266

Globulin (g/L)a

20-30

29.5 (24.8, 31.9)

27.5 (23.5, 30.6)

26.7 (23.2, 29.8)

0.112

Albumin/Globulina

1.5-2.5

1.4 (1.3, 1.6)

1.5 (1.3, 1.7)

1.5 (1.2, 1.7)

0.316

γ-glutamyltransferase (U/L)a

5-55

60.5 (39.8, 134.5)

62.0 (39.3, 118.0)

67.5 (31.3, 97.5)

0.716

Alkaline phosphatase (U/L)a

35-134

93.0 (71.8, 113.3)

102.0 (78.0, 137.0)

91.0 (77.0, 110.8)

0.170

5-Nucleotidase (U/L)a

0-10

3.5 (2.0, 5.8)

3.0 (2.0, 6.0)

3.0 (2.0, 4.5)

0.403

Total biliary acid (μmol/L)a

0-15

7.4 (4.0, 22.4)

7.1 (3.6, 15.6)

7.1(4.0,14.7)

0.553

Cholinesterase (U/L)a

3000-10500

5940.8 ± 2522.3

6074.5 ± 2231.3

6007.5 ± 2498.1

0.927

Pre-albumin (mg/L)a

100-400

119.5 (68.8, 157.9)

118.0 (75.0, 175.3)

110.0 (56.0, 172.5)

0.493

Glucose (mmol/L)a

3.9-6.2

5.0 (4.4, 6.0)

5.1 (4.6, 5.8)

5.1 (4.4, 5.6)

0.653

Blood urea nitrogen (mmol/L)a

1.7-7.2

4.9 (3.5, 5.7)

5.0 (3.8, 6.0)

5.2 (3.3, 6.2)

0.633

Creatinine (μmol/L)a

45-117

76.2 (69.1, 83.7)

73.5 (64.1, 84.0)

72.2 (62.7, 83.7)

0.488

Uric acid (μmol/L)b

119-417

243.0 ± 77.3

257.3 ± 92.8

251.7 ± 72.9

0.547

Retinol-binding protein (mg/L)a

15-70

25.4 (16.1, 34.5)

28.1 (17.4, 35.0)

27.2 (16.3, 35.7)

0.990

Cystatin C (mg/L)a

0-1.2

1.1 (0.8, 1.2)

1.0 (0.9, 1.2)

1.0 (0.9, 1.2)

0.999

Carcinoembryonic antigen, (ng/mL)a

0-5

2.0 (1.6, 2.9)

2.3 (1.4, 3.5)

2.2 (1.8, 3.3)

0.683

Alpha-fetoprotein (ng/mL)a

0-20

124.1 (9.8, 865.8)

130.7 (8.5, 957.9)

382.4 (36.2, 1052.0)

0.116

Ferritin (ng/mL)a

0-322

353.0 (138.9, 431.3)

204.5 (116.7, 342.0)

232.9 (174.6, 392.0)

0.281

Cancer antigen 125 (KU/L)a

0-35

12.8 (8.7, 38.3)

15.5 (9.6, 32.5)

17.3 (9.9, 58.2)

0.701

Cancer antigen 153 (KU/L)a

0-35

11.5 (9.6, 16.0)

9.3 (7.5, 13.6)

10.6 (7.8, 17.2)

0.206

Cancer antigen 199 (KU/L)a

0-35

13.3 (8.0, 23.1)

13.3 (6.4, 26.3)

12.8 (6.6, 17.2)

0.779

Prothrombin time (sec)a

10.5-13.5

12.0 (11.4, 13.2)

11.9 (11.0, 12.9)

12.2 (11.3, 13.2)

0.462

PT% (%)a

80-130

94.5 (84.2, 100.7)

91.3 (81.6, 109.4)

91.0 (77.2, 101.1)

0.603

International standard ratioa

0.85-1.15

1.0 (1.0, 1.2)

1.0 (1.0, 1.1)

1.1 (1.0, 1.1)

0.437

D-fibrinogen (g/L)a

2-4

2.5 (2.2, 3.2)

2.8 (2.2, 3.5)

2.5 (2.1, 3.1)

0.348

activated partial thrombo -plastin time (sec)b

28-40

35.2 ± 7.6

33.9 ± 7.3

37.1 ± 8.0

0.032

Thrombin time (sec)a

11-14

14.4 (13.6, 15.7)

14.4 (13.7, 15.4)

14.5(13.7,16.0)

0.872

  1. aData were expressed as median (25th percentile, 75th percentile).
  2. bData were expressed as mean ± SD.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us